XBiotech is undertaking one of the most unique and important drug development initiatives in the world: A cancer therapy in Phase III clinical studies treats the disease by undermining the tumor’s ability to grow, spread and do harm to vital organ systems; First-in-class True Human™ therapeutic antibodies provide safer, better tolerated, and more efficacious therapies than ever before; And new manufacturing processes pioneered at XBiotech will reduce the cost and complexity of the drug development process and, in turn, reduce the cost of medications.
XBiotech is always recruiting. Please review current opportunities below.
11.19.13 - XBiotech Hosts Dr. Charles Dinarello at its Facilities in Austin, TX: XBiotech announced today that it hosted Dr. Charles Dinarello at its Facilities…more
09.18.13 - XBiotech Announces Collaboration with US Oncology Research in Pivotal Phase III Trial for Anti-Cancer Drug Xilonix™: XBiotech, a privately held biotechnology company, announced today its collaboration…more
09.04.13 - XBiotech Announces it is Developing Therapy for MRSA: XBiotech announced today that it has completed discovery and has begun pre-clinical development…more
08.29.13 - XBiotech Announces Addition to its Board of Directors: XBiotech announced today that Dr. Fabrizio Bonanni has joined the Company…more
© 2013 XBiotech USA, Inc. | All Rights Reserved